<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9502500</journal-id>
<journal-id journal-id-type="pubmed-jr-id">8794</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Cancer Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Clin. Cancer Res.</journal-id>
<journal-title-group>
<journal-title>Clinical cancer research : an official journal of the American Association for Cancer Research</journal-title>
</journal-title-group>
<issn pub-type="ppub">1078-0432</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29093017</article-id>
<article-id pub-id-type="pmc">5679124</article-id>
<article-id pub-id-type="doi">10.1158/1078-0432.CCR-17-0615</article-id>
<article-id pub-id-type="manuscript">NIHMS894050</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A Population of Heterogeneous Breast Cancer Patient Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild Type Tumors</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Evans</surname>
<given-names>Kurt W</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yuca</surname>
<given-names>Erkan</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Akcakanat</surname>
<given-names>Argun</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Scott</surname>
<given-names>Stephen M</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arango</surname>
<given-names>Natalia Paez</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zheng</surname>
<given-names>Xiaofeng</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Ken</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tapia</surname>
<given-names>Coya</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tarco</surname>
<given-names>Emily</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eterovic</surname>
<given-names>Agda K</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Black</surname>
<given-names>Dalliah M</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Litton</surname>
<given-names>Jennifer K</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yap</surname>
<given-names>Timothy A</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tripathy</surname>
<given-names>Debu</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mills</surname>
<given-names>Gordon B</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Meric-Bernstam</surname>
<given-names>Funda</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</aff>
<aff id="A2">
<label>2</label>Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</aff>
<aff id="A3">
<label>3</label>Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</aff>
<aff id="A4">
<label>4</label>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</aff>
<aff id="A5">
<label>5</label>Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</aff>
<aff id="A6">
<label>6</label>Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</aff>
<aff id="A7">
<label>7</label>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</aff>
<author-notes>
<corresp id="FN1">Corresponding author: Funda Meric-Bernstam, MD, UT MD Anderson Cancer Center, 1400 Holcombe Boulevard, Unit 455, Houston, TX 77030, Tel#: 713/794/1226, Fax#: 713/563-0566, <email>fmeric@mdanderson.org</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p>The authors declare no potential conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>12</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<day>01</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>11</month>
<year>2018</year>
</pub-date>
<volume>23</volume>
<issue>21</issue>
<fpage>6468</fpage>
<lpage>6477</lpage>
<!--elocation-id from pubmed: 10.1158/1078-0432.CCR-17-0615-->
<abstract>
<sec id="S1">
<title>Background</title>
<p id="P1">Breast cancer patients who do not respond to neoadjuvant therapy have a poor prognosis. There is a pressing need for novel targets and models for preclinical testing. Here we report characterization of breast cancer patient derived xenografts (PDXs) largely generated from residual tumors following neoadjuvant chemotherapy.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P2">PDXs were derived from surgical samples of primary or locally recurrent tumors. Normal and tumor DNA sequencing, RNASeq and Reverse Phase Protein Arrays (RPPA) were performed. Phenotypic profiling was performed by determining efficacy of a panel of standard and investigational agents.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P3">Twenty-six PDXs were developed from 25 patients. Twenty-two were generated from residual disease following neoadjuvant chemotherapy, and 24 were from triple negative breast cancer (TNBC). These PDXs harbored a heterogeneous set of genomic alterations and represented all TNBC molecular subtypes. On RPPA, PDXs varied in extent of PI3K and MAPK activation. PDX also varied in their sensitivity to chemotherapeutic agents. PI3K, mTOR and MEK inhibitors repressed growth but did not cause tumor regression. PARP inhibitor talazoparib caused dramatic regression in 5 of 12 PDXs. Notably 4 of 5 talazoparib-sensitive models did not harbor germline <italic>BRCA1/2</italic> mutations, but several had somatic alterations in homologous repair pathways, including ATM deletion and BRCA2 alterations.</p>
</sec>
<sec id="S4">
<title>Conclusions</title>
<p id="P4">PDXs capture the molecular and phenotypic heterogeneity of TNBC. Here we show that PARP inhibition can have activity beyond germline BRCA1/2 altered tumors, causing regression in a variety of molecular subtypes. These models represent an opportunity for the discovery of rational combinations with targeted therapies and predictive biomarkers.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Patient derived xenografts</kwd>
<kwd>PARP inhibitors</kwd>
<kwd>precision medicine</kwd>
<kwd>genomics</kwd>
<kwd>somatic mutation</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>